#USA #Minneapolis #Bio-Techne #Oxford Nanopore #genetics

Bio-Techne and Oxford Nanopore Technologies Strengthen Their Collaboration

Bio-Techne Corporation has announced a significant expansion of its partnership with Oxford Nanopore Technologies, which is set to drive the development of innovative genetic tools until 2032. This newly enhanced agreement follows the successful introduction of the AmplideX® Nanopore Carrier Plus Kit in early 2025, reflecting Bio-Techne's commitment to advancing genetic testing solutions that streamline workflows in clinical and research settings.

Expanding the Genetic Horizons

The expanded commercial rights allow Bio-Techne to develop a wider array of genetic products, leveraging Oxford Nanopore’s cutting-edge technology. The collaboration aims to accelerate the creation of targeted enrichment sequencing kits designed specifically for screening and diagnosing heritable genetic conditions. This initiative underscores both companies' dedication to enhancing laboratory capabilities worldwide.

Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, remarked, "This collaboration deepens our engagement with Oxford Nanopore, propelling us towards greater innovation in diagnostics. The effort not only aims to simplify the diagnostic process but also seeks to provide laboratories with richer insights into genetic disorders."

Rosemary Dokos, Chief Product and Marketing Officer of Oxford Nanopore Technologies, commented on the partnership, stating, "By combining Bio-Techne's expertise in diagnostics with our advanced molecular sensing technology, we can expedite the availability of new genetic testing solutions. Our goal is to make testing more accessible and efficient for healthcare providers and patients alike."

About the Companies

Bio-Techne Corporation

Bio-Techne Corporation is globally recognized for its pioneering contributions to life sciences. The company offers a comprehensive range of tools, reagents, and diagnostic products that support scientific research and clinical testing. In the fiscal year 2025, Bio-Techne achieved over $1.2 billion in net sales, employing approximately 3,100 professionals worldwide. Their extensive product portfolio includes hundreds of thousands of items used by researchers to explore biological processes and diseases, facilitating drug discovery and clinical diagnostics.

Oxford Nanopore Technologies

Oxford Nanopore Technologies has revolutionized the field of molecular sensing, introducing a new generation of technology aimed at providing rapid and accessible DNA and RNA analysis. Their innovative platform is not only expanding its applications to include proteins and metabolites but is also being utilized in over 125 countries to advance the understanding of various biological entities, including humans, plants, and microorganisms. The company’s vision is to democratize access to genomic information, allowing for comprehensive analyses that inform health and environmental management.

The Path Forward

With this new agreement, both Bio-Techne and Oxford Nanopore Technologies are poised to lead the future of genetic diagnostics. By creating a framework for defining and proposing new product portfolios, the partnership aims to enhance genetic testing, making it simpler and more efficient. As the demand for precise and reliable diagnostic methods continues to grow, their collaborative efforts represent a significant step towards meeting these expectations in the healthcare domain.

To stay updated on Bio-Techne’s advancements, visit Bio-Techne or engage with them on social media platforms like LinkedIn, Twitter, and YouTube. And for more information about the cutting-edge technology provided by Oxford Nanopore, explore Oxford Nanopore Technologies.